Pfizer Inc: Upgrades Estimates for Coronavirus Vaccine Sales

- Article Top Advertisement -

Pfizer Inc raised its estimates for coronavirus vaccine sales for the full year to about $ 32 billion, and said it expects another $ 22 billion from sales of the male coronavirus pill.

- Article Inline Advertisement 1-

The vaccine, based on mRNA technology, like that of rival Moderna, is used in more than 160 countries, including the United States, with Pfizer targeting more than 4 billion doses of the vaccine in 2022, up from 2 billion. installments last year.

- Advertisement -

Paxlovid, the coronavirus pill, has shown a promising reduction in hospitalization and deaths in high-risk patients, and the company expects to produce at least 120 million Pill Cards this year.

However, the company announced that it expects adjusted earnings per share for the whole of this year in the range of $ 6.35 to $ 6.55, lower than the converging estimates in a FactSet poll for adjusted earnings of $ 6.71 in 2022. Lower than expected Its revenue forecasts are also fluctuating, with the company setting the bar in the range of $ 98 to $ 102 billion, compared to the convergent estimates for revenue of $ 103.2 billion.

Pfizer’s lower-than-expected forecasts put pressure on the pharmaceutical industry, which fell more than 3.6% in pre-conference trading.

For the fourth quarter, the pharmaceutical industry reported better-than-expected earnings, with revenues still slightly lower than analysts’ estimates despite a nearly 105% increase.

In particular, the company’s net profit jumped to $ 3.39 billion or 59 cents per share, compared to 847 million dollars or 15 cents per share in the same period last year.

Excluding non-recurring earnings, adjusted earnings per share rose to $ 1.08 per share from 43 cents per share in the fourth quarter of 2020, beating analysts’ convergent estimates in a FactSet poll that set the bar at 87 cents per share. .

At the same time, the pharmaceutical industry’s revenue jumped 104.9% to $ 23.84 billion, but was lower than convergent estimates, as analysts at FactSet expected $ 24.16 billion.

Revenue from the Comirnaty coronavirus vaccine was $ 12.5 billion, surpassing $ 12.38 billion in sales estimates.

Source: Capital

- Article Bottom Advertisement -


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles